The multi-tissue DNA methylation estimator of chronological age (DNAm-age) has been associated with a wide range of exposures and health outcomes. Still, it is unclear how DNAm-age can have such broad relationships and how it can be best utilized as a biomarker. Understanding DNAm-age's molecular relationships is a promising approach to address this critical knowledge gap. In this review, we discuss the existing literature regarding DNAm-age's molecular relationships in six major categories: animal model systems, cancer processes, cellular aging processes, immune system processes, metabolic processes, and nucleic acid processes. We also present perspectives regarding the future of DNAm-age research, including the need to translate a greater number of ongoing research efforts to experimental and animal model systems.
Background
Since its introduction in 2013, the multi-tissue 353-CpG DNA methylation-based estimator of chronological age (DNAm-age) has gained notoriety as the leading molecular measure of human aging. DNAm-age -which is also referred to as "the epigenetic clock" and "epigenetic age" -is not the only DNA methylation-based predictor of chronological age (Hannum et al., 2013; Weidner et al., 2014; Bocklandt et al., 2011; Huang et al., 2015; Zbiec-Piekarska et al., 2015; Florath et al., 2014) , but it is the estimator with the greatest organismal and tissue applicability (Fig. 1) . In contrast to other methylation-based predictors which are based on data from blood cells or one tissue type, DNAm-age was developed using data from 82 Illumina DNA methylation array datasets. These datasets were comprised of 7844 non-cancer human samples from 51 healthy tissues or cell types. Horvath (2013) began by regressing a transformed version chronological age on 21,369 CpGs -shared between the Illumina 27 K and 450 K methylation array platforms -using a penalized regression elastic net model. 353 CpGs were selected by the elastic net: 193 were hypermethylated with age and 160 were hypomethylated. The weighted average of the regression coefficients from each of the 353 CpG sites was then used to develop an algorithm to calculate one measure of age prediction, DNAm-age. With only a few exceptions (e.g. breast tissue, dermal fibroblasts, heart tissue, uterine endometrium, and skeletal muscle), DNAm-age has a prediction performance error of ± 3.6 years across cell types. It is still unclear why DNAm-age performs poorly in these tissues, but it is believed to be due to some intrinsic property of the tissues themselves (Horvath, 2013) .
After the release of the seminal DNAm-age paper, researchers began reporting statistically and biologically significant associations of DNAm-age with a host of disease states. Many of these relationships persisted even after accounting for chronological age, and were identified in tissues where DNAm-age was known to have high predictive performance. One such study reported that every 10 unit increase in Body Mass Index (BMI) was significantly associated with a 3.3 year increase in the hepatocyte DNAm-age of their study subjects (Horvath et al., 2014) . As time progressed, more evidence suggested that DNAmage was not simply a predictor of chronological age. Rather, DNAm-age was a novel measure of biological age that could be indicative of disease risk. One of the most compelling studies that supported this biological age theory was a meta-analysis of 13 population-based cohorts amounting to 13,089 individuals. This study found that increases in blood DNAm-age were predictive of mortality even when accounting for chronological age and additional disease states and lifestyle risk factors (Chen et al., 2016) . To date, DNAm-age continues to be associated with a growing number of health-related outcomes and exposures ranging from Parkinson's disease and human immunodeficiency virus (HIV) infection to cumulative lifetime stress and air pollution (Fig. 2) 
